RT Journal Article
SR Electronic
T1 Assessment of multiplex digital droplet RT-PCR as an accurate diagnosis tool for SARS-CoV-2 detection in nasopharyngeal swabs and saliva samples
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.02.20166694
DO 10.1101/2020.08.02.20166694
A1 Cassinari, Kévin
A1 Alessandri-Gradt, Elodie
A1 Chambon, Pascal
A1 Charbonnier, Françoise
A1 Gracias, Ségolène
A1 Beaussire, Ludivine
A1 Alexandre, Kevin
A1 Sarafan-Vasseur, Nasrin
A1 Houdayer, Claude
A1 Etienne, Manuel
A1 Caron, François
A1 Plantier, Jean Christophe
A1 Frebourg, Thierry
YR 2020
UL http://medrxiv.org/content/early/2020/08/04/2020.08.02.20166694.abstract
AB RT-qPCR on nasopharyngeal swabs is currently the reference COVID-19 diagnosis method. We developed a multiplex RT-ddPCR assay, targeting six SARS-CoV-2 genomic regions, and evaluated it on nasopharyngeal swabs and saliva samples collected from 130 COVID-19 positive or negative ambulatory individuals, who presented symptoms suggestive of mild or moderate Sars-CoV2 infection. The 6-plex RT-ddPCR assay was shown to have 100% sensitivity on nasopharyngeal swabs and a higher sensibility than RT-qPCR on saliva (85% versus 62%). Saliva samples from 2 individuals with negative results on nasopharyngeal swabs were found to be positive. These results show that multiplex RT-ddPCR should represent an alternative and complementary tool for the diagnosis of COVID-19, in particular to control RT-qPCR ambiguous results, and its application to saliva an appropriate strategy for repetitive sampling and testing individuals for whom nasopharyngeal swabbing is not possible.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the French Defence Innovation Agency (Contract N 2020 68 0918 00 00 00 00)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by the institutional French ethics committee (2020T3-12_RIPH3 HPS_2020-A00920-39)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data relevant to this study and not included here will be made available upon reasonable request.